Annual EBIT
-$159.38 M
+$104.25 M+39.54%
31 December 2023
Summary:
Intra-Cellular Therapies annual earnings before interest & taxes is currently -$159.38 million, with the most recent change of +$104.25 million (+39.54%) on 31 December 2023. During the last 3 years, it has risen by +$71.85 million (+31.07%). ITCI annual EBIT is now -873.95% below its all-time high of -$16.32 million.ITCI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$38.85 M
-$11.13 M-40.13%
30 September 2024
Summary:
Intra-Cellular Therapies quarterly earnings before interest & taxes is currently -$38.85 million, with the most recent change of -$11.13 million (-40.13%) on 30 September 2024. Over the past year, it has dropped by -$9.14 million (-30.75%). ITCI quarterly EBIT is now -359612.96% below its all-time high of -$10.80 thousand, reached on 30 June 2013.ITCI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$121.62 M
-$9.14 M-8.12%
30 September 2024
Summary:
Intra-Cellular Therapies TTM earnings before interest & taxes is currently -$121.62 million, with the most recent change of -$9.14 million (-8.12%) on 30 September 2024. Over the past year, it has increased by +$51.08 million (+29.58%). ITCI TTM EBIT is now -1126020.37% below its all-time high of -$10.80 thousand, reached on 30 June 2013.ITCI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.5% | -30.8% | +29.6% |
| 3 y3 years | +31.1% | +49.8% | +53.4% |
| 5 y5 years | +1.8% | -6.8% | +21.5% |
ITCI EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +44.2% | -85.4% | +55.8% | -8.1% | +62.5% |
| 5 y | 5 years | -3.5% | +44.2% | -85.4% | +55.8% | -8.1% | +62.5% |
| alltime | all time | -874.0% | +44.2% | <-9999.0% | +55.8% | <-9999.0% | +62.5% |
Intra-Cellular Therapies EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$38.85 M(+40.1%) | -$121.62 M(+8.1%) |
| June 2024 | - | -$27.72 M(+32.3%) | -$112.48 M(-14.7%) |
| Mar 2024 | - | -$20.95 M(-38.6%) | -$131.94 M(-17.2%) |
| Dec 2023 | -$159.38 M(-39.5%) | -$34.10 M(+14.8%) | -$159.38 M(-7.7%) |
| Sept 2023 | - | -$29.71 M(-37.0%) | -$172.70 M(-13.0%) |
| June 2023 | - | -$47.18 M(-2.5%) | -$198.61 M(-17.0%) |
| Mar 2023 | - | -$48.39 M(+2.1%) | -$239.36 M(-9.2%) |
| Dec 2022 | -$263.63 M(-7.7%) | -$47.41 M(-14.8%) | -$263.63 M(-12.8%) |
| Sept 2022 | - | -$55.63 M(-36.7%) | -$302.22 M(-6.7%) |
| June 2022 | - | -$87.92 M(+21.0%) | -$323.91 M(+6.2%) |
| Mar 2022 | - | -$72.66 M(-15.5%) | -$305.13 M(+6.8%) |
| Dec 2021 | -$285.69 M(+23.6%) | -$86.00 M(+11.2%) | -$285.69 M(+9.5%) |
| Sept 2021 | - | -$77.32 M(+11.8%) | -$261.02 M(+8.9%) |
| June 2021 | - | -$69.14 M(+29.9%) | -$239.63 M(+1.8%) |
| Mar 2021 | - | -$53.22 M(-13.2%) | -$235.36 M(+1.8%) |
| Dec 2020 | -$231.23 M(+50.1%) | -$61.33 M(+9.6%) | -$231.23 M(+9.2%) |
| Sept 2020 | - | -$55.94 M(-13.8%) | -$211.66 M(+10.2%) |
| June 2020 | - | -$64.87 M(+32.2%) | -$192.10 M(+15.4%) |
| Mar 2020 | - | -$49.09 M(+17.5%) | -$166.40 M(+8.0%) |
| Dec 2019 | -$154.01 M(-5.1%) | -$41.77 M(+14.8%) | -$154.01 M(-0.6%) |
| Sept 2019 | - | -$36.38 M(-7.1%) | -$154.87 M(-4.3%) |
| June 2019 | - | -$39.17 M(+6.7%) | -$161.88 M(+0.0%) |
| Mar 2019 | - | -$36.70 M(-13.9%) | -$161.88 M(-0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$162.27 M(+58.2%) | -$42.62 M(-1.8%) | -$162.27 M(+6.7%) |
| Sept 2018 | - | -$43.39 M(+10.8%) | -$152.11 M(+14.8%) |
| June 2018 | - | -$39.17 M(+5.6%) | -$132.47 M(+18.4%) |
| Mar 2018 | - | -$37.08 M(+14.2%) | -$111.92 M(+9.1%) |
| Dec 2017 | -$102.59 M(-11.0%) | -$32.46 M(+36.6%) | -$102.59 M(+5.4%) |
| Sept 2017 | - | -$23.76 M(+27.6%) | -$97.36 M(-5.5%) |
| June 2017 | - | -$18.62 M(-32.9%) | -$103.02 M(-11.1%) |
| Mar 2017 | - | -$27.75 M(+1.9%) | -$115.95 M(-0.6%) |
| Dec 2016 | -$115.32 M(+10.1%) | -$27.23 M(-7.5%) | -$116.69 M(-1.4%) |
| Sept 2016 | - | -$29.42 M(-6.7%) | -$118.30 M(-2.3%) |
| June 2016 | - | -$31.54 M(+10.7%) | -$121.04 M(+8.9%) |
| Mar 2016 | - | -$28.50 M(-1.2%) | -$111.18 M(+5.8%) |
| Dec 2015 | -$104.79 M(+241.5%) | -$28.83 M(-10.3%) | -$105.08 M(+14.9%) |
| Sept 2015 | - | -$32.16 M(+48.3%) | -$91.45 M(+39.2%) |
| June 2015 | - | -$21.69 M(-3.2%) | -$65.70 M(+35.3%) |
| Mar 2015 | - | -$22.40 M(+47.4%) | -$48.55 M(+58.2%) |
| Dec 2014 | -$30.68 M(+16.9%) | -$15.20 M(+136.9%) | -$30.68 M(+30.6%) |
| Sept 2014 | - | -$6.42 M(+41.6%) | -$23.50 M(+7.5%) |
| June 2014 | - | -$4.53 M(-0.1%) | -$21.86 M(+26.1%) |
| Mar 2014 | - | -$4.54 M(-43.4%) | -$17.34 M(+35.4%) |
| Dec 2013 | -$26.24 M(+60.3%) | -$8.01 M(+67.7%) | -$12.81 M(+167.3%) |
| Sept 2013 | - | -$4.78 M(>+9900.0%) | -$4.79 M(>+9900.0%) |
| June 2013 | - | -$10.80 K | -$10.80 K |
| Dec 2012 | -$16.36 M | - | - |
FAQ
- What is Intra-Cellular Therapies annual earnings before interest & taxes?
- What is the all time high annual EBIT for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual EBIT year-on-year change?
- What is Intra-Cellular Therapies quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly EBIT year-on-year change?
- What is Intra-Cellular Therapies TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM EBIT year-on-year change?
What is Intra-Cellular Therapies annual earnings before interest & taxes?
The current annual EBIT of ITCI is -$159.38 M
What is the all time high annual EBIT for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual earnings before interest & taxes is -$16.32 M
What is Intra-Cellular Therapies annual EBIT year-on-year change?
Over the past year, ITCI annual earnings before interest & taxes has changed by +$104.25 M (+39.54%)
What is Intra-Cellular Therapies quarterly earnings before interest & taxes?
The current quarterly EBIT of ITCI is -$38.85 M
What is the all time high quarterly EBIT for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly earnings before interest & taxes is -$10.80 K
What is Intra-Cellular Therapies quarterly EBIT year-on-year change?
Over the past year, ITCI quarterly earnings before interest & taxes has changed by -$9.14 M (-30.75%)
What is Intra-Cellular Therapies TTM earnings before interest & taxes?
The current TTM EBIT of ITCI is -$121.62 M
What is the all time high TTM EBIT for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM earnings before interest & taxes is -$10.80 K
What is Intra-Cellular Therapies TTM EBIT year-on-year change?
Over the past year, ITCI TTM earnings before interest & taxes has changed by +$51.08 M (+29.58%)